ArticleFrontiers in human neuroscience2024
The population based cognitive testing in subjects with SARS-CoV-2 (POPCOV2) study: longitudinal investigation of remote cognitive and fatigue screening in PCR-positive cases and negative controls.
Article in Frontiers in human neuroscience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The majority of people infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) only show mild respiratory symptoms. However, some patients with SARS-CoV-2 display neurological symptoms. Data on the exact prevalence and course of cognitive symptoms are often limited to patient reported outcomes or studies recruited at specialized centers. Methods: For this prospective, non-interventional population based POPCOV2 study, 156 subjects who performed SARS-CoV-2 testing in the Düsseldorf metropolitan area at public test centers between December 2020 and February 2022 were recruited by handouts. SARS-CoV-2-positive and negatively tested subjects were included within the first seven days after the PCR test results. Cognitive testing was performed at baseline during home quarantine and after 4-6 as well as 12-14 weeks of follow-up. Individuals were examined remotely by videocalls using the Symbol Digit Modalities Test (SDMT) and the Montreal Cognitive Assessment (MoCA) in addition to the Brief Fatigue Inventory (BFI) and the Beck Depression Inventory-Fast Screen (BDI-FS). Results: At baseline, the SARS-CoV-2-positive group presented with higher levels of fatigue in the BFI. In both the SARS-CoV-2-positive and SARS-CoV-2-negative groups, some subjects presented attention and memory deficits, defined as a z-score < -1,65 on the SDMT or < 26 points on the MoCA (SDMT: 22.9% in the positive and 8.8% in the negative group, Conclusion: These results support previous evidence that mild SARS-CoV-2 infections are associated with increased fatigue. However, we found relevant rates of cognitive impairment not only in the infected but also in the control group. This underlines the importance of including a control group in such investigations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.